{"disease":{"id":"moderate-hepatic-impairment","name":"moderate hepatic impairment"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05624944","title":"A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Taisho Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05116826","title":"Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Genfit","has_results":false},{"nct_id":"NCT07231029","title":"A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Taisho Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04116476","title":"Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Tanabe Pharma America, Inc.","has_results":false},{"nct_id":"NCT05224609","title":"A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05610657","title":"A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Agios Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT07343960","title":"A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04995484","title":"A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04223635","title":"Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Daiichi Sankyo","has_results":true},{"nct_id":"NCT04534699","title":"Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"KBP Biosciences","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}